Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CoTIL-01
- Development stage
- Discontinued
- Lead developer
- Instil Bio
- Modality
- Cell Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous
01
Overview
**CoTIL-01** is a gene therapy product consisting of autologous tumor infiltrating lymphocytes (TIL) genetically engineered to express a co-stimulatory receptor (CoStAR). The therapy is designed to enhance immunologic cytotoxicity and provide T lymphocyte replacements, with the aim to boost anti-tumor immune response. It was developed for administration to patients with platinum-resistant ovarian carcinoma, and possibly other cancers and related diseases. The developer and originator is Instil Bio (UK) Limited, incorporating technology initially from Immetacyte. Its highest phase reached was Phase 1/2, but development for platinum-resistant ovarian carcinoma was discontinued[1][7].
- Brand names
- CoTIL-01CoTIL01CoTIL 01
- Other names
- Immetacyte
02
Targets
FOLR1 (FRα)
Beyond the preview
Go deeper on CoTIL-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CoTIL-01.